{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:07:38Z","timestamp":1779944858032,"version":"3.53.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetic kidney disease (T2DKD) affects 20\u201340% of patients with type 2 diabetes mellitus and has become the leading cause of end-stage renal disease globally. Early identification of patients at risk of rapid progression remains challenging, as existing prediction models often rely on complex indicators unsuitable for primary care settings. This study aimed to develop and validate a machine learning model using routine clinical parameters to predict T2DKD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study enrolled 349 patients diagnosed with T2DKD according to clinical criteria at Quzhou People\u2019s Hospital in China between June 2022 and June 2025. From 36 baseline characteristics, four core predictors were identified through least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression. Six machine learning models were constructed, and model performance was evaluated by discrimination, calibration, and clinical net benefit. Model interpretability was assessed using SHapley Additive exPlanations (SHAP) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), aspartate aminotransferase (AST), diabetic peripheral neuropathy (DPN), and age were identified as independent core predictors. The neural network (NN) model achieved optimal performance in the test dataset, with an area under the curve (AUC) of 0.742, satisfactory calibration (Hosmer\u2013Lemeshow P\u00a0=\u00a00.2020), the lowest Brier score (0.2105), and superior clinical net benefit across risk thresholds of 0.2\u20130.6. SHAP analysis confirmed stable feature importance rankings between training and test datasets (Pearson r = 0.976) and revealed synergistic interactions among MASLD, AST, and DPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A NN model incorporating four routine clinical indicators effectively predicts T2DKD progression risk. This cost-effective tool is suitable for clinical practice and community health services, offering a scalable solution for early intervention and prognosis improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1858808","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:57:07Z","timestamp":1779944227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of an explainable neural network model for predicting progression in type 2 diabetic kidney disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Binfeng","family":"Xiong","sequence":"first","affiliation":[{"name":"Jin hua Graduate Joint Training Base, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzheng","family":"Duan","sequence":"additional","affiliation":[{"name":"The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Lin","sequence":"additional","affiliation":[{"name":"Jin hua Graduate Joint Training Base, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Quzhou Hospital of Traditional Chinese Medicine","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13098-023-01202-x","article-title":"Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis","volume":"15","author":"Fenta","year":"2023","journal-title":"Diabetol Metab Syndrome"},{"key":"B2","doi-asserted-by":"publisher","first-page":"112326","DOI":"10.1016\/j.diabres.2025.112326","article-title":"Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study","volume":"226","author":"Mart\u00ednez-Montoro","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40620-024-02152-x","article-title":"The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease","volume":"38","author":"Kleibert","year":"2025","journal-title":"J Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.12.1506","article-title":"Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database","volume":"26","author":"Folkerts","year":"2020","journal-title":"J Managed Care Specialty Pharm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04650417","article-title":"Diabetic kidney disease","volume":"13","author":"Tong","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12882-018-0821-9","article-title":"Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review","volume":"19","author":"Norris","year":"2018","journal-title":"BMC Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"107555","DOI":"10.1016\/j.compbiomed.2023.107555","article-title":"The enlightening role of explainable artificial intelligence in medical & healthcare domains: A systematic literature review","volume":"166","author":"Ali","year":"2023","journal-title":"Comput Biol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ehjdh\/ztae080","article-title":"Machine learning based prediction models for cardiovascular disease risk using electronic health records data: systematic review and meta-analysis","volume":"6","author":"Liu","year":"2025","journal-title":"Eur Heart J - Digital Health"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.001","article-title":"Machine learning approaches enable the discovery of therapeutics across domains","volume":"33","author":"Chhibbar","year":"2025","journal-title":"Mol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"109962","DOI":"10.1016\/j.compbiomed.2025.109962","article-title":"An extensive review on infectious disease diagnosis using machine learning techniques and next generation sequencing: State-of-the-art and perspectives","volume":"189","author":"Aalam","year":"2025","journal-title":"Comput Biol Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12967-022-03339-1","article-title":"Prediction of 3-year risk of diabetic kidney disease using machine learning based on electronic medical records","volume":"20","author":"Dong","year":"2022","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.37766\/inplasy2024.9.0038","article-title":"Machine learning-based risk predictive models for diabetic kidney disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s449397","article-title":"Design of machine learning algorithms and internal validation of a kidney risk prediction model for type 2 diabetes mellitus","volume":"17","author":"Wang","year":"2024","journal-title":"Int J Gen Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05444-0","article-title":"Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease","volume":"64","author":"Chan","year":"2021","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1870","article-title":"Development and validation of a prediction model for future estimated glomerular filtration rate in people with type 2 diabetes and chronic kidney disease","volume":"6","author":"Gregorich","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70031","article-title":"Executive summary of the asian pacific society of nephrology clinical practice guideline on diabetic kidney disease\u20142025 update","volume":"30","author":"Liew","year":"2025","journal-title":"Nephrology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.20944\/preprints202306.1245.v1","article-title":"Significance of diabetic kidney disease biomarkers in predicting metabolic-associated fatty liver disease","volume":"11","author":"Bae","year":"2023","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110563","DOI":"10.1016\/j.diabres.2023.110563","article-title":"Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes","volume":"197","author":"Wei","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1032814","article-title":"Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy","volume":"13","author":"Yan","year":"2022","journal-title":"Front Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.01.008","article-title":"The interplay between nonalcoholic fatty liver disease and kidney disease","volume":"26","author":"Truong","year":"2022","journal-title":"Clinics Liver Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2020.1745851","article-title":"Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches","volume":"128","author":"Sharma","year":"2020","journal-title":"Arch Physiol Biochem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0130","article-title":"Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Seo","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac382","article-title":"Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients","volume":"107","author":"Sun","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s330741","article-title":"The association of aspartate aminotransferase\/alanine aminotransferase ratio with diabetic nephropathy in patients with type 2 diabetes","volume":"14","author":"Xu","year":"2021","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s442165","article-title":"Clinical evidence of the relationship between alanine aminotransferase and diabetic kidney disease","volume":"17","author":"Bi","year":"2024","journal-title":"Diabetes Metab Syndrome Obes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108235","DOI":"10.1016\/j.jdiacomp.2022.108235","article-title":"Aspartate aminotransferase to alanine aminotransferase ratio and the risk of diabetic nephropathy progression in patients with type 2 diabetes mellitus: A biopsy-based study","volume":"36","author":"Wu","year":"2022","journal-title":"J Diabetes its Complications"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.3390\/jcm12124089","article-title":"Association between diabetic peripheral neuropathy as measured using a point-of-care sural nerve conduction device and urinary albumin excretion in patients with type 2 diabetes","volume":"12","author":"Fukuda","year":"2023","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0519-9","article-title":"Correlation between different stages of diabetic nephropathy and neuropathy in patients with T2DM: A cross-sectional controlled study","volume":"9","author":"Xu","year":"2018","journal-title":"Diabetes Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/med-2023-0894","article-title":"Molecular mechanism and intervention measures of microvascular complications in diabetes","volume":"19","author":"Xu","year":"2024","journal-title":"Open Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27198","DOI":"10.1038\/s41598-024-78828-y","article-title":"Assessing the diagnostic utility of urinary albumin-to-creatinine ratio as a potential biomarker for diabetic peripheral neuropathy in type 2 diabetes mellitus patients","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/met.2023.0007","article-title":"Metabolic syndrome and inflammation from young to mid-adulthood and subclinical kidney damage in middle-aged Australians","volume":"21","author":"Liu","year":"2023","journal-title":"Metab Syndrome Related Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.3390\/ijms22157783","article-title":"Glucose variability: how does it work","volume":"22","author":"Klimontov","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00507","article-title":"Genetic and epigenetic studies in diabetic kidney disease","volume":"10","author":"Gu","year":"2019","journal-title":"Front Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015020124","article-title":"APOL1 genotype and race differences in incident albuminuria and renal function decline","volume":"27","author":"Peralta","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1858808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:57:11Z","timestamp":1779944231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1858808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1858808"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1858808","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1858808"}}